Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 March, 2018 08:08 IST
Panacea Biotec receives EIR for oncology manufacturing facility
Source: IRIS | 12 Mar, 2018, 10.40AM
Comments  |  Post Comment

Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration ('USFDA') indicating the formal closure of the Inspection conducted by USFDA, at its Pharmaceutical Formulation Facility for Oncology Parenteral and Oral Solids Dosage at Malpur, Baddi, District Solan, Himachal Pradesh, India.

Shares of the company gained Rs 9.7, or 3.45%, to trade at  Rs 290.75.  The total volume of shares traded  was  12,527 at the BSE (10.29 a.m., Monday).

Panacea Biotec Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Tata Steel identified as successful resolution application for acquisition of Bhushan Steel - 23-Mar-2018 12:36
Vakrangee ties up with Blue Dart Express - 23-Mar-2018 09:54
Suven Life Sciences secures 3 overseas product patents - 22-Mar-2018 12:24
Cox & Kings sells 11.58% stake in subsidiary - 22-Mar-2018 12:20
Steel Strips Wheels receives 7,000 wheel order from UK aftermarket - 22-Mar-2018 10:37
Zensar Technologies acquires US based Cynosure Inc - 22-Mar-2018 10:33
IRB Infrastructure Developers wins Rs 34 bn Hapur bypass BOT project - 22-Mar-2018 10:18
Sun Pharma announces USFDA approval of ILUMYA drug - 22-Mar-2018 09:39
Ashok Leyland bags orders for 2,100 buses from Tamil Nadu - 21-Mar-2018 10:17
Suzlon designs and produces India's longest wind turbine blade - 21-Mar-2018 10:11
Mphasis partners with Plug and Play - 21-Mar-2018 09:55
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer